Document Detail

Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia.
MedLine Citation:
PMID:  12681367     Owner:  NLM     Status:  MEDLINE    
Vascularity is increased in the bone marrow of patients with chronic myeloid leukemia (CML) and high vascular endothelial growth factor (VEGF) levels correlate with worse survival. We analyzed the significance of VEGF-receptor 1 (VEGF-R1) and VEGF-R2 levels in bone marrow samples from 170 CML patients (137 chronic, 24 accelerated, and 9 blastic phase). Median VEGF-R1 and VEGF-R2 levels were 4.66 and 2-fold, respectively, that in normal control samples. Receptor levels did not correlate with disease phase or other host and disease features examined. Chronic phase CML patients with increased VEGF-R2 levels had significantly inferior survival than patients without receptor up-regulation (P=0.009). Patients in accelerated/blastic phase CML with elevated VEGF-R2 expression had marginally worse survival (P=0.05). In contrast, high VEGF-R1 levels did not correlate with a specific CML phase, characteristic, or outcome. Our findings support VEGF-R2 over-expression as an independent prognostic indicator for shortened survival in patients with CML.
Srdan Verstovsek; Scott Lunin; Hagop Kantarjian; Taghi Manshouri; Stefan Faderl; Jorge Cortes; Francis Giles; Maher Albitar
Related Documents :
6776767 - Sex and splenectomy in agnogenic myeloid metaplasia.
8109597 - What is the contribution of molecular studies to the diagnosis of bcr-abl-positive dise...
16750667 - Evaluation of mlpa for the detection of cryptic subtelomeric rearrangements.
8065157 - Bone marrow cellularity in myeloid stem cell disorders: impact of age correction.
10440157 - Comparison of stress/rest myocardial perfusion tomography, dipyridamole and dobutamine ...
20690087 - Clinical implication of gastrointestinal bleeding in degenerative aortic stenosis: an u...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Leukemia research     Volume:  27     ISSN:  0145-2126     ISO Abbreviation:  Leuk. Res.     Publication Date:  2003 Jul 
Date Detail:
Created Date:  2003-04-08     Completed Date:  2003-07-01     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  7706787     Medline TA:  Leuk Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  661-9     Citation Subset:  IM    
Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, P.O. Box 428, Houston, TX 77030, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Blast Crisis
Bone Marrow / metabolism,  pathology
Case-Control Studies
Disease Progression
Endothelial Growth Factors / metabolism
Gene Expression Regulation, Leukemic
Intercellular Signaling Peptides and Proteins / metabolism
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis,  metabolism*,  pathology
Lymphokines / metabolism
Middle Aged
Neovascularization, Pathologic
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor Receptor-1 / metabolism*
Vascular Endothelial Growth Factor Receptor-2 / metabolism*
Vascular Endothelial Growth Factors
Reg. No./Substance:
0/Endothelial Growth Factors; 0/Intercellular Signaling Peptides and Proteins; 0/Lymphokines; 0/Vascular Endothelial Growth Factor A; 0/Vascular Endothelial Growth Factors; EC Endothelial Growth Factor Receptor-1; EC Endothelial Growth Factor Receptor-2
Comment In:
Leuk Res. 2003 Jul;27(7):571-3   [PMID:  12681355 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Expression of serologically identified tumor antigens in acute leukemias.
Next Document:  G protein-coupled receptor kinases regulate metabotropic glutamate receptor 5 function and expressio...